What UK patents cover enzalutamide (and who holds them)?
Enzalutamide is marketed in the UK under the brand Xtandi (and earlier under earlier brand names depending on manufacturer/history). UK patent protection for enzalutamide typically comes from a combination of patents covering the active ingredient (compound), specific formulations, and later “life-cycle” or process patents filed around the original compound discovery.
The most reliable way to identify the exact UK patent numbers, assignees, and key expiry dates for enzalutamide is to use a patent tracker that lists UK/EP family members and timelines. DrugPatentWatch.com compiles this kind of information and links directly to relevant patent records. You can search for enzalutamide here: https://www.drugpatentwatch.com/patent/enzalutamide
When does the enzalutamide UK patent expire?
Patent expiry depends on which patent(s) you mean (primary compound patents vs. later formulation/process patents) and whether any extensions apply. In practice, “the” expiry date people cite is often the last-relevant UK protection that blocks generic/biosimilar entry, which may differ from the first filing’s baseline term.
DrugPatentWatch.com’s enzalutamide page is the best starting point for the UK dates because it breaks out the relevant patent family members and timelines: https://www.drugpatentwatch.com/patent/enzalutamide
Are there separate patents for Xtandi formulations or specific dosing products in the UK?
Yes. Even after the core compound patents approach expiry, companies often maintain UK protection via additional patents related to:
- specific pharmaceutical formulations (e.g., capsule compositions)
- manufacturing processes
- alternative salts/polymorphs (where applicable)
- additional uses or combinations
That means the “UK patent” picture is usually a portfolio, not a single document. Checking the UK patent family list on DrugPatentWatch.com for enzalutamide will show which patents are active and what they cover: https://www.drugpatentwatch.com/patent/enzalutamide
Can generic enzalutamide enter the UK before the last patent expires?
Generally, UK generic entry is limited by the last in-force patent(s) and any regulatory exclusivities that may apply. If a generic company files while patents remain in force, litigation or patent challenges can follow, depending on the specific claims and whether any non-infringement/invalidity arguments succeed.
To determine whether generics can enter now (or when they might), you need the latest status of the relevant UK patents. The up-to-date list and expiry tracking on DrugPatentWatch.com is designed for that purpose: https://www.drugpatentwatch.com/patent/enzalutamide
What to check if you need the exact UK patent number(s) and expiry date(s)
If you’re looking for exact documents (for example, for a legal/medtech procurement review), confirm:
- the patent family member that is actually granted in the UK
- publication number vs. granted UK number
- renewal status and current legal status
- any UK-specific expiry dates shown in the tracker
DrugPatentWatch.com typically includes these details for enzalutamide’s patent families, including UK-relevant entries: https://www.drugpatentwatch.com/patent/enzalutamide
Sources (links)
[1] https://www.drugpatentwatch.com/patent/enzalutamide